Managed Healthcare Executive1d
FDA Approves First BTK Inhibitor as First-Line Therapy for Mantle Cell Lymphoma
The drug received accelerated approval in October 2017 as monotherapy for adults with MCL who have received at least one ...
pharmaphorum5d
FDA says no to AZ's Fasenra for nasal polyp indication
It is also being developed for other indications including hypereosinophilic syndrome (HES) and eosinophilic oesophagitis, with phase 3 readouts in both of those uses expected later this year.
Hosted on MSN1d
BIIB Secures FDA Nod for Monthly Maintenance Dosing of Alzheimer's Drug
Biogen BIIB announced that the FDA has approved a monthly maintenance dosing version for its intravenously (IV) administered ...
CBM Lifemotion® Achieves MDR CE Mark for New Lifemotion® ECMO System
Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions ...
precisionmedicineonline1d
Eisai, Biogen's Leqembi Receives FDA Approval for Chronic Alzheimer's Maintenance Treatment
With this approval, patients who receive the anti-amyloid drug biweekly for 18 months can then consider switching to a monthly dosing regimen.